Revive Therapeutics signs asset purchase agreement with Newscope Capital to acquire the full rights to PharmaTher's IP relating to psilocybin

Revive Therapeutics Ltd. (CSE:RVV) (OTCMKTS:RVVTF) said that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement with Newscope Capital Corporation to acquire the full rights to PharmaTher Inc.’s intellectual property relating to psilocybin.

PharmaTher, a wholly-owned subsidiary of Newscope, is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals.

READ: Revive Therapeutics closes previously announced bought deal offering for aggregate gross proceeds of $23M

Under the agreement, Revive will pay aggregate consideration of up to C$10 million which will be satisfied as follows: (i) $3 million in cash will be paid on the closing date; (ii) $4 million will be satisfied through the issuance of securities in the capital of Revive and (iii) up to $3 million, in either cash or securities in the capital of Revive, in the event that Revive achieves certain milestones, which include Revive obtaining FDA orphan drug designation for psilocybin in the treatment of stroke, traumatic brain injury, or cancer, the commencement of a Phase 2 clinical trial and the regulatory filing for market authorization, such as US Food and Drug Administration (FDA) approval.

In addition to the purchase price, Revive will also pay Newscope a low single-digit royalty on all future net sales of products derived from the acquired assets.

The acquired assets will include all intellectual and work property derived from pre-clinical research activities from the National Health Research Institutes (NHRI) in traumatic brain injury and stroke, as it relates to psilocybin with the aim to obtain FDA Orphan Drug Designation.

They will also comprise key provisional patent applications with the US Patent and Trademark Office, which include:

• Psilocybin in the Treatment of Neurological Brain Injury – United States Provisional Application Serial No. 63/011,493 – Relates to pharmaceutical compositions comprising psilocybin and their use for the treatment of neurological brain injuries and migraines.          
• Use of Psilocybin in the Treatment of Cancer, United States Provisional Application Serial No. 63/113,913 – Psilocybin’s use of significant unmet medical needs for Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.        
• Psilocybin Pharmaceutical Combination Therapies, United States Provisional Application Serial No. 63/125,106 – Novel combinations of certain FDA approved drugs with psilocybin as a potential therapeutic option to reduce the side effects and improve the effectiveness of psilocybin to treat neurological disorders.

“With this acquisition, we have solidified our foundation in having a leading psychedelics pharmaceutical platform with a focus on proprietary psilocybin-based therapeutics that includes the development of an oral thin film product in collaboration with the University of Wisconsin-Madison, a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform developed by Dr Gavin Williams, Professor and Researcher at North Carolina State University, a clinical study with the University of Wisconsin evaluating psilocybin in the treatment of methamphetamine use disorder, and PharmaTher’s psilocybin research initiatives and intellectual property in stroke, traumatic brain injury, cancer and drug combinations,” said Michael Frank, CEO of Revive in a statement.

“We are now in a position to advance our psilocybin program for future clinical development in various unmet clinical needs in mental health, cancer and neurological disorders,” he added.

Fabio Chianelli, CEO of Newscope commented: “We are pleased to have partnered PharmaTher’s psilocybin program with Revive as they have positioned themselves as a leader in psilocybin pharmaceutical development with their unique product and delivery technology offerings as well as their commitment in commercializing a biosynthetic form of psilocybin for long-term sustainability.”

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and coronavirus (COVID-19).

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Contact the author at [email protected]

Story by ProactiveInvestors